CTSO · Cytosorbents Corp · Webcasts, Transcripts & Audio
$4.00
-0.05 (-1.23%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“approximately $4.4 million in unrestricted cash and cash equivalents and $1.5 million of non-current restricted cash which may not be sufficient to fund the Company's operations beyond the next twelve months from the issuance of these condensed consolidated financial statements. These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$12.61M
Shares
3.14M
Volume · Oct 5
5878
Avg daily vol (18 sessions)
12.3K
Cytosorbents Corp Webcasts
Earnings calls, investor updates, investor days and conferences for Cytosorbents Corp (CTSO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼16.9%
$8.11M
−$12.20M
'22 Q3
22-11-03
▼12.9%
$9.39M
−$766,126
'22 Q4
23-03-09
▲8.7%
$9.45M
−$7.33M
'23 Q1
23-05-02
▲10.9%
$9.42M
−$6.15M
'23 Q2
23-08-02
▲8.6%
$8.81M
−$9.19M
'23 Q3
23-11-09
▼7.7%
$8.67M
−$6.57M
'23 Q4
24-03-15
▼4.9%
$8.99M
−$6.09M
'24 Q1
24-05-09
▼6.1%
$8.84M
−$4.29M
'24 Q2
24-08-14
▼2.2%
$8.61M
−$2.77M
'24 Q3
24-10-01
▲5.6%
$9.15M
−$7.57M
'24 Q4
25-03-04
▼2.9%
$8.73M
−$1.48M
'25 Q1
25-05-14
▲8.8%
$9.62M
$1.95M
'25 Q2
25-06-30
▲10.1%
$9.48M
−$3.17M
'25 Q3
25-11-13
▲0.9%
$9.23M
−$5.50M
'25 Q4
26-03-25
▲1.6%
$8.86M
−$5.13M
'26 Q1
26-05-13
LATEST
▲0.2%
$9.63M
−$4.42M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Cytosorbents Corp (CTSO) Q2 2026 Earnings Call Transcript
Positive tone
Cytosorb commercial sales and Germany restructuring
HemaDefend BGA universal plasma strategic optionality
Operating cash flow break-even progress
Revenue
$9.63M
▲ 0.2% YoY Diluted EPS
$-1.40
▼ 333.3% YoY Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Cytosorbents Corp (CTSO) Q1 2026 Earnings Call Transcript
Positive tone
DrugSorb-ATR U.S. regulatory pathway
Core CytoSorb international commercial performance
Geopolitical disruption in the Middle East
Revenue
$8.86M
▲ 1.6% YoY Diluted EPS
$-1.60
Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Cytosorbents Corp (CTSO) Q4 2025 Earnings Call Transcript
Positive tone
DrugSorb-ATR FDA resubmission
Germany restructuring and sales recovery
Path to operating cash flow break-even
Revenue
$9.23M*
▲ 0.9% YoY Gross margin
73.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Cytosorbents Corp (CTSO) Q3 2025 Earnings Call Transcript
Positive tone
DrugSorb-ATR FDA Pathway
Germany Sales Restructuring
Cash Flow Breakeven Path
Revenue
$9.48M
▲ 10.1% YoY Diluted EPS
$-1.00
Gross margin
70.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Cytosorbents Corp (CTSO) Q2 2025 Earnings Call Transcript
Positive tone
CytoSorb product and sepsis clinical evidence
DrugSorb ATR regulatory process
Gross margin performance
Revenue
$9.62M
▲ 8.8% YoY Diluted EPS
$0.60
Gross margin
70.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Cytosorbents Corp (CTSO) Q1 2025 Earnings Call Transcript
Positive tone
DrugSorb-ATR regulatory status
Core CytoSorb business performance
Germany sales reorganization
Revenue
$8.73M
▼ 2.9% YoY Diluted EPS
$-0.40
Gross margin
71.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Cytosorbents Corp (CTSO) Q4 2024 Earnings Call
Revenue
$9.15M*
▲ 5.6% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-01
Cytosorbents Corp (CTSO) Q3 2024 Earnings Call Transcript
Positive tone
DrugSorb ATR U.S. and Canada regulatory pathway
CytoSorb international core business growth
PuriFi pump as enabling technology
Revenue
$8.61M
▼ 2.2% YoY Diluted EPS
$-1.00
Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Cytosorbents Corp (CTSO) Q2 2024 Earnings Call Transcript
Positive tone
DrugSorb-ATR Regulatory Submission
Revenue and Product Sales Growth
Taiwan Market Opportunity
Revenue
$8.84M
▼ 6.1% YoY Diluted EPS
$-1.60
Gross margin
73.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Cytosorbents Corp (CTSO) Q1 2024 Earnings Call Transcript
Positive tone
DrugSorb-ATR regulatory submissions
Clinical evidence and new indications
Product sales growth and post-COVID recovery
Revenue
$8.99M
▼ 4.9% YoY Diluted EPS
$-2.20
Gross margin
76.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-15
Cytosorbents Corp (CTSO) Q4 2023 Earnings Call Transcript
Balanced tone
STAR-T trial and regulatory pathway for DrugSorb-ATR
India distribution partnership with Eris Lifesciences/ARRIS
Sales performance and growth across regions
Revenue
$8.67M
▼ 7.7% YoY Diluted EPS
$-2.40
Gross margin
61.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Cytosorbents Corp (CTSO) Q3 2023 Earnings Call Transcript
Revenue
$8.81M
▲ 8.6% YoY Diluted EPS
$-4.20
Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Cytosorbents Corp (CTSO) Q2 2023 Earnings Call Transcript
Revenue
$9.42M
▲ 10.9% YoY Diluted EPS
$-3.00
Gross margin
63.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Cytosorbents Corp (CTSO) Q1 2023 Earnings Call Transcript
Revenue
$9.45M
▲ 8.7% YoY Diluted EPS
$-3.40
Gross margin
57.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Cytosorbents Corp (CTSO) Q4 2022 Earnings Call Transcript
Revenue
$9.39M
▼ 12.9% YoY Diluted EPS
$-0.40
Gross margin
61.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cytosorbents Corp (CTSO) Q3 2022 Earnings Call Transcript
Revenue
$8.11M
▼ 16.9% YoY Diluted EPS
$-5.60
Gross margin
44.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Cytosorbents Corp (CTSO) Q2 2022 Earnings Call Transcript
Revenue
$8.50M
▼ 29.3% YoY Diluted EPS
$-5.00
Gross margin
58.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Cytosorbents Corp (CTSO) Q1 2022 Earnings Call Transcript
Revenue
$8.69M
▼ 18% YoY Diluted EPS
$-4.20
Gross margin
73.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Cytosorbents Corp (CTSO) Q4 2021 Earnings Call Transcript
Revenue
$10.78M
▼ 9.8% YoY Diluted EPS
$-5.00
Gross margin
71.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-13
Cytosorbents Corp (CTSO) Q3 2021 Earnings Call Transcript
Revenue
$9.76M
▼ 7.5% YoY Diluted EPS
$-3.00
Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Cytosorbents Corp (CTSO) Q2 2021 Earnings Call Transcript
Revenue
$12.02M
▲ 22.8% YoY Diluted EPS
$-2.20
Gross margin
77.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Cytosorbents Corp (CTSO) Q1 2021 Earnings Call Transcript
Revenue
$10.60M
▲ 21.7% YoY Diluted EPS
$-2.00
Gross margin
74.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Cytosorbents Corp (CTSO) Q4 2020 Earnings Call Transcript
Revenue
$11.96M
▲ 60.9% YoY Diluted EPS
$0.00
Gross margin
78.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Cytosorbents Corp (CTSO) Q3 2020 Earnings Call Transcript
Revenue
$10.55M
▲ 73% YoY Diluted EPS
$-0.40
Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Cytosorbents Corp (CTSO) Q2 2020 Earnings Call Transcript
Revenue
$9.79M
▲ 57.2% YoY Diluted EPS
$-1.60
Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Cytosorbents Corp (CTSO) Q1 2020 Earnings Call Transcript
Revenue
$8.71M
▲ 67.7% YoY Diluted EPS
$-2.00
Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Cytosorbents Corp (CTSO) Q4 2019 Earnings Call
Revenue
$7.43M
▲ 22.2% YoY Diluted EPS
$-2.60
Gross margin
71.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts